866-997-4948(US-Canada Toll Free)

Prostate Cancer - US Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Dec 2010

Category :

Cancer

No. of Pages : 223 Pages


GlobalData\'s pharmaceutical report, Prostate Cancer US Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the US prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the US prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the US prostate cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized US prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profiles including opportunity for target products. 
  • Technology trends analytic framework to assess the strength of the pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the US Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in the US.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the US prostate cancer therapeutics market. 
  • Understanding the treatment preferences of physicians for each disease state and across treatment flow.
  • Accessing market sizing forecasts and quantified growth opportunities in the US prostate cancer therapeutics market up to 2020.
  • Quantifying the patient population in the US to better design product pricing and launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
  • Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
  • Track drug sales in the US prostate cancer therapeutics market from 2001 to 2020.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the US prostate cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Disease Overview 9
2.1 Overview 9
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 10
2.1.2 Jewett-Whitmore system 11
2.2 Epidemiology 12
2.3 Etiology 12
2.4 Symptoms 13
2.4.1 Localized or Locally Advanced Prostate Cancer 13
2.4.2 Metastatic Prostate Cancer 13
2.5 Diagnosis 14
2.5.1 Digital Rectal Examination 14
2.5.2 Prostate Specific Antigen Test 14
2.5.3 Transrectal Ultrasound 15
2.5.4 Prostate Biopsy 15
2.6 Pathology 16
2.6.1 Grading 16
2.7 Treatment 16
2.7.1 Watchful Waiting 16
2.7.2 Radiation therapy 16
2.7.3 Surgery 17
2.7.4 Hormone therapy 18
2.7.5 Chemotherapy Options 19
2.7.6 Other Treatments Being Studied 19
2.8 Treatment Guidelines 20

3 Market Characterization 21
3.1 The US 21
3.1.1 Market Size 21
3.1.2 Drivers and Restraints 28
3.1.3 Forecasts 31
3.1.4 Drug Sales 38
3.1.5 Pricing & Reimbursements 41

4 Competitor Assessment 42
4.1 Strategic Competitor Assessment 42
4.1.1 Overview 42
4.1.2 Benchmarking 43
4.1.3 Current Competitor Assessment 47
4.2 Launch Analysis and Sales Forecasts 48
4.3 Product Profiles 49
4.3.1 Taxotere (docetaxel) 50
4.3.2 Casodex (Bicalutamide) 54
4.3.3 Zoladex (Goserelin) 59
4.3.4 Provenge (sipuleucel-T) 61
4.3.5 Jevtana (cabazitaxel) 63
4.3.6 Eligard (leuprolide acetate) 65
4.3.7 Lupron (Leuprolide acetate) 69
4.3.8 Prostap (leuprolide acetate) 72
4.3.9 Firmagon (degarelix) 74
4.3.10 Vantas (Histrelin) 76
4.3.11 Novantrone (Mitoxantrone hydrochloride) 79
4.3.12 Emcyt (estramustine) 81
4.3.13 Trelstar (triptorelin) 82
4.3.14 Eulexin 84
4.3.15 Delestrogen 86
4.3.16 Gynodiol 88
4.3.17 Estrace tablet 89
4.3.18 Tace 90
4.3.19 Nilandrone 91
4.3.20 Premarin 92
4.3.21 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 93

5 Pipeline Assessment 94
5.1 Overview 94
5.2 Pipeline Analysis by Phase of Development 95
5.3 Pipeline by Mechanism of Action 96
5.4 Strategic Pipeline Assessment 97
5.4.1 Technology Trends Analytical Framework 97
5.5 Trends in Prostate Cancer Pipeline 98
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 98
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 98
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 99
5.6 Partners in Research and Development 100
5.6.1 Licensing Agreements by Phase of Development 100
5.6.2 Licensing Agreements by Geography 103
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 103
5.7 Most Promising Drugs’ Profiles 105
5.7.1 Aflibercept (VEGF Trap) 106
5.7.2 Ipilimumab 108
5.7.3 Abiraterone Acetate (CB7630) 111
5.7.4 Sprycel (dasatinib) 113
5.7.5 MDV3100 116
5.8 Prostate Cancer Pipeline – Phase III 118
5.9 Prostate Cancer Pipeline – Phase II 119
5.10 Prostate Cancer Pipeline – Phase I 123
5.11 Prostate Cancer Pipeline – Pre-clinical Phase 125
5.12 Prostate Cancer Pipeline – Phase III (Recent Failures) 126
5.13 Key Takeaway 126

6 Unmet Need and Target Product Profile 127
6.1 Unmet Need 129
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 129
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 130
6.2 Opportunity for Target Product 131
6.3 Target Product Profile 133
6.3.1 Ideal Characteristics 133
6.3.2 Target Product Description 133
6.4 Key Takeaway 134

7 Strategic Assessment 135
7.1 Key Events Impacting the Future Market 135
7.2 Market Impact Analysis 136
7.3 Future Market Scenario 136
7.4 Company Analysis 138
7.4.1 Market Leadership 138
7.4.2 Future Players in the Market 138
7.5 Key Takeaway 138

8 Company Profiles 139
8.1 Sanofi-aventis 139
8.1.1 Business Description 139
8.1.2 Financial Overview 141
8.1.3 SWOT Analysis 141
8.1.4 Oncology Focus 146
8.2 Pfizer Inc. 147
8.2.1 Business Description 147
8.2.2 Financial Overview 148
8.2.3 SWOT Analysis 148
8.2.4 Oncology Focus 154
8.3 AstraZeneca 156
8.3.1 Business Description 156
8.3.2 Financial Overview 157
8.3.3 SWOT Analysis 158
8.3.4 Oncology Focus 162
8.4 Bristol-Myers Squibb 163
8.4.1 Business Description 163
8.4.2 Financial Overview 165
8.4.3 SWOT Analysis 165
8.4.4 Oncology Focus 171
8.5 Medivation 173
8.5.1 Business Description 173
8.5.2 SWOT Analysis 173
8.5.3 Oncology Focus 176
8.6 Takeda Pharmaceuticals 177
8.6.1 Business Description 177
8.6.2 SWOT Analysis 177
8.7 Dendreon Corporation 179
8.7.1 Business Description 179
8.7.2 SWOT Analysis 179
8.8 Johnson and Johnson 183
8.8.1 Business Description 183
8.8.2 SWOT Analysis 184
8.8.3 Oncology Focus 191
8.9 Auron Healthcare GmbH 192
8.9.1 Business Description 192
8.10 Oncogenex Pharmaceuticals, Inc. 192
8.10.1 Business Description 192
8.11 Agennix AG 192
8.11.1 Business Description 192
8.12 GTx, Inc. 193
8.12.1 Business Description 193
8.13 GlaxoSmithKline plc. 193
8.13.1 Business Description 193
8.13.2 Financial Overview 194
8.13.3 SWOT Analysis 194
8.13.4 Oncology Focus 201

9 M&A Analysis 203
9.1 Key Highlights 203
9.2 Key Deals’ Analysis 205
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 205
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 205
9.2.3 Tolmar Holding Acquires QLT USA from QLT 205
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 205
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 206
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 206
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 206
9.2.8 GPC Biotech Merges with Agennix 206
9.2.9 Eli Lilly Acquires ImClone 206
9.2.10 BBM Holdings Acquires YM BioSciences 206
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 207
9.3 M&A Deals by Geography 207
9.4 M&A Deals by Deal Size 208

10 Expert Opinion 209
10.1 The US 209

11 Appendix 211
11.1 Market Definitions 211
11.2 Abbreviations 211
11.3 Research Methodology 213
11.3.1 Coverage 213
11.3.2 Secondary Research 214
11.3.3 Forecasting 214
11.3.4 Primary Research 217
11.3.5 Expert Panel validation 217
11.3.6 Contact Us 217
11.3.7 Disclaimer 217
11.3.8 Sources 218

List of Table


Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Table 3: Prostate Cancer Therapeutics Market, US, Sales Value ($bn), 2001-2009 20
Table 4: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 22
Table 5: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2001-2009 23
Table 6: Prostate Cancer Therapeutics Market, The US, Treatment Usage Patterns (000s), 2001-2009 25
Table 7: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 30
Table 8: Prostate Cancer, US, Annual Cost of Therapy ($), 2009-2020 31
Table 9: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2009-2020 32
Table 10: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2009-2020 33
Table 11: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 37
Table 12: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 37
Table 13: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 41
Table 14: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 42
Table 15: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 43
Table 16: Prostate Cancer, US, Benchmarking Major Marketed Products, 2010 47
Table 17: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 53
Table 18: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 64
Table 19: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 65
Table 20: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 66
Table 21: Prostate Cancer, Global, Lupron, Efficacy End Point for Three Products 68
Table 22: Prostate Cancer, Global, Lupron, Incidence of Adverse Effects, 2010 69
Table 23: Prostate Cancer, Global, Licensing Agreements, 2009-2010 98
Table 24: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 100
Table 25: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 101
Table 26: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 117
Table 27: Prostate Cancer, Global, Phase I Pipeline, August 2010 119
Table 28: Prostate Cancer, Global, Phase II Pipeline, August 2010 122
Table 29: Prostate Cancer, Global, Phase III Pipeline, August 2010 130
Table 30: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 139
Table 31: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 140
Table 32: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 197
Table 33: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 198
Table 34: Prostate Cancer, Global, M&A Deals by Geography, 2010 208

List of Chart


Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19
Figure 2: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2001-2009 20
Figure 3: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009 21
Figure 4: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2001-2009 23
Figure 5: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2001-2009 24
Figure 6: Prostate Cancer Therapeutics Market, US, Market Drivers and Restraints, 2009 27
Figure 7: Prostate Cancer Therapeutics Market, The US, Historical Events Impact on the Market, 2010 29
Figure 8: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020 30
Figure 9: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2009-2020 31
Figure 10: Prostate Cancer Therapeutics Market, US, Patient Volume (000s), 2009-2020 32
Figure 11: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (000s), 2009-2020 33
Figure 12: Prostate Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2010-2020 35
Figure 13: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 36
Figure 14: Prostate Cancer Therapeutics Market, US, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 38
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 44
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 45
Figure 17: Prostate Cancer Therapeutics Market, US, Sales Forecast by Therapies, 2001-2020 46
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 48
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 50
Figure 20: Prostate Cancer, US, Taxotere, Sales ($m), 2004-2020 51
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 52
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 56
Figure 23: Prostate Cancer, US, Casodex, Sales ($m), 1995-2020 57
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 58
Figure 25: Prostate Cancer, US, Zoladex, Sales Forecast ($m), 1998-2020 59
Figure 26: Prostate Cancer, US, Provenge, Sales Forecast ($m), 2010-2020 61
Figure 27: Prostate Cancer, US, Jevtana, Sales Forecast ($m), 2010-2020 62
Figure 28: Prostate Cancer, Global, Eligard , Chemical Structure 63
Figure 29: Prostate Cancer, US, Leuprolide (Eligard, Lupron), Sales Forecast ($m), 2001-2020 67
Figure 30: Prostate Cancer, Global, Lupron, Chemical Structure 68
Figure 31: Prostate Cancer, US, Leuprolide (Eligard, Lupron, Prostap), Sales Forecast ($m), 2001-2020 71
Figure 32: Prostate Cancer, Global, Firmagon, Chemical Structure 72
Figure 33: Prostate Cancer, US, Firmagon, Sales Forecast ($m), 2008-2020 73
Figure 34: Prostate Cancer, Global, Vantas, Chemical Structure 74
Figure 35: Prostate Cancer, US, Vantas, Sales Forecast ($m), 2004-2020 76
Figure 36: Prostate Cancer, Global, Novatrone, Chemical Structure 76
Figure 37: Prostate Cancer, US, Mitoxantrone, Sales Forecast ($m), 2001-2020 78
Figure 38: Prostate Cancer, Global, Emcyt, Chemical Structure 78
Figure 39: Prostate Cancer, US, Estramustine, Sales Forecast ($m), 2001-2020 79
Figure 40: Prostate Cancer, Global, Trelstar, Chemical Structure 80
Figure 41: Prostate Cancer, Global, Eulexin, Chemical Structure 82
Figure 42: Prostate Cancer, Global, Delestrogen, Chemical Structure 84
Figure 43: Prostate Cancer, Global, Gynodiol, Chemical Structure 85
Figure 44: Prostate Cancer, Global, Estrace, Chemical Structure 86
Figure 45: Prostate Cancer, Global, Tace, Chemical Structure 87
Figure 46: Prostate Cancer, Global, Nilandrone, Chemical Structure 88
Figure 47: Prostate Cancer, Global, Premarin, Chemical Structure 89
Figure 48: Prostate Cancer, US, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 90
Figure 49: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 91
Figure 50: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 92
Figure 51: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 93
Figure 52: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 94
Figure 53: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 95
Figure 54: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 96
Figure 55: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 99
Figure 56: Prostate Cancer, Global, Aflibercept, Chemical Structure 102
Figure 57: Prostate Cancer, US, Aflibercept, Sales Forecast ($m), 2013-2020 104
Figure 58: Prostate Cancer, US, Ipilimumab , Sales Forecast ($m), 2014-2020 106
Figure 59: Prostate Cancer, Global, Abiraterone, Chemical Structure 107
Figure 60: Prostate Cancer, US, Abiraterone, Sales Forecast ($m), 2012-2020 109
Figure 61: Prostate Cancer, Global, Zibotentan, Chemical Structure 110
Figure 62: Prostate Cancer, US, Zibotentan , Sales Forecast ($m), 2012-2020 112
Figure 63: Prostate Cancer, US, Sprycel , Sales Forecast ($m), 2013-2020 113
Figure 64: Prostate Cancer, Global, MDV3100, Chemical Structure 114
Figure 65: Prostate Cancer, US, MDV3100 , Sales Forecast ($m), 2012-2020 116
Figure 66: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 133
Figure 67: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 134
Figure 68: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 134
Figure 69: Prostate Cancer, US, Prostate Cancer, Opportunity and Unmet Need, 2010 135
Figure 70: Prostate Cancer, US, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 138
Figure 71: Prostate Cancer, US, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 138
Figure 72: Prostate Cancer, Global, Key Events Impacting the Future Market 141
Figure 73: Prostate Cancer, US, Implications for Future Market Competition, 2010 142
Figure 74: Prostate Cancer, Global, Future Players in the Market, 2010 144
Figure 75:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 146
Figure 76: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 147
Figure 77: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 148
Figure 78: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 153
Figure 79: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 155
Figure 80: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 161
Figure 81: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 162
Figure 82: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 164
Figure 83: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 165
Figure 84: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 169
Figure 85: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 169
Figure 86: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 170
Figure 87: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 171
Figure 88: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 172
Figure 89: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 178
Figure 90: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 179
Figure 91: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 180
Figure 92: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 184
Figure 93: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 186
Figure 94: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 191
Figure 95: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 197
Figure 96: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 200
Figure 97: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 206
Figure 98: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 207
Figure 99: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 212
Figure 100: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 212
Figure 101: Prostate Cancer, US, Key Data Inputs from KOL Interviews, July 2010 213
Figure 102: GlobalData Market Forecasting Model 220

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *